These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780 [TBL] [Abstract][Full Text] [Related]
11. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. Kim HL; Steinberg GD J Urol; 2000 Sep; 164(3 Pt 1):627-32. PubMed ID: 10953112 [TBL] [Abstract][Full Text] [Related]
12. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860 [TBL] [Abstract][Full Text] [Related]
13. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Arcangeli G; Strigari L; Arcangeli S Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521 [TBL] [Abstract][Full Text] [Related]
14. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485 [TBL] [Abstract][Full Text] [Related]
15. Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy. de Angelis M; Scheipner L; Siech C; Jannello LMI; Baudo A; Bello FD; Goyal JA; Vitucci K; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI Clin Genitourin Cancer; 2024 Aug; 22(4):102119. PubMed ID: 38852435 [TBL] [Abstract][Full Text] [Related]
16. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation. Gamal El-Deen HS J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344 [TBL] [Abstract][Full Text] [Related]
17. Management dilemmas in bladder cancer: radical TUR +/- systemic chemotherapy in the treatment of muscle-invasive bladder cancer. Feneley MR; Mellon JK Semin Urol Oncol; 2000 Nov; 18(4):300-7. PubMed ID: 11101094 [TBL] [Abstract][Full Text] [Related]
18. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer. Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP; Bilen MA; Jani AB Am J Clin Oncol; 2019 Jan; 42(1):36-41. PubMed ID: 29912804 [TBL] [Abstract][Full Text] [Related]